Trial Profile

Atorvastatin pre-treatment influences the risk of percutaneous coronary intervention study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin; HMG-CoA reductase inhibitors
Indications Angina pectoris; Coronary artery disease; Myocardial infarction
Focus Therapeutic Use
Acronyms TIPS

Most Recent Events

22 Feb 2011 Long-term follow-up results published in the American Journal of Cardiology.
01 Sep 2009 Results published in the American Journal of Cardiology.
27 Jan 2009 Biomarkers information updated

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com